Advair Powder
Product Images NDC 0173-0696

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Advair (NDC 0173-0696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 01)

Chemical structure of fluticasone propionate, one of the active ingredients in ADVAIR DISKUS containing fluticasone propionate and salmeterol. The diagram shows the molecular configuration with labeled atoms and bonds.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 02)

Chemical structure diagram showing two distinct molecular structures, representing the active ingredients of ADVAIR DISKUS: fluticasone propionate and salmeterol.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 03)

A line graph comparing the percent change in FEV1 over 12 weeks and at an endpoint for four groups: ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph shows the ADVAIR DISKUS group achieving the highest percent change in FEV1.*

FDA Label Image

S:\project Files\a\advair Diskus Nda 021077\figures\advair-diskus-spl-graphic-04.jpg (Advair Diskus Spl Graphic 04)

A line graph showing percent change in FEV1 over 12 hours following baseline on Day 1 for four groups: ADVAIR DISKUS 100/50 twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph tracks respiratory function changes during the study period.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 05)

A line graph showing the percent change in FEV1 relative to day 1 baseline over a 12-hour period for different treatments: ADVAIR DISKUS 100/50 twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph compares lung function changes across these groups with time on the x-axis (hours) and percent change on the y-axis.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 06)

A line chart comparing the percentage change in FEV1 over 24 weeks among three groups: ADVAIR DISKUS 250/50, Salmeterol 50 mcg, and placebo. The chart shows higher improvement in the ADVAIR DISKUS group compared to Salmeterol and placebo. The x-axis represents weeks, and the y-axis represents percent change in FEV1.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 07)

A line graph depicting percentage change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo groups. The x-axis represents weeks, and the y-axis shows percent change in FEV1 from baseline. Data points indicate higher improvement for ADVAIR DISKUS compared to other groups during the study.*

FDA Label Image

Figure A (Advair Diskus Spl Graphic 08)

An instructional illustration showing the labeled parts of an ADVAIR DISKUS inhaler. The device is purple with an outer case, mouthpiece, thumb grip, lever, and counter clearly marked. The label on the device indicates a strength of 100/50 micrograms of fluticasone propionate and salmeterol inhalation powder.*

FDA Label Image

Figure B (Advair Diskus Spl Graphic 09)

An instructional illustration showing a hand holding an Advair Diskus inhaler, demonstrating a horizontal sliding motion to prepare the device for inhalation.*

FDA Label Image

Figure C (Advair Diskus Spl Graphic 10)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler device, demonstrating how to operate or prepare the inhaler by pushing the lever to load a dose for inhalation.*

FDA Label Image

Figure D (Advair Diskus Spl Graphic 11)

Illustration showing a woman holding an ADVAIR DISKUS inhaler near her mouth, demonstrating the use of this powder inhalation device for respiratory delivery. The woman appears to be preparing to inhale the medication.*

FDA Label Image

Figure E (Advair Diskus Spl Graphic 12)

An instructional illustration showing a woman using the ADVAIR DISKUS inhaler. She holds the purple respiratory powder inhaler device close to her mouth, demonstrating proper inhalation technique for medication delivery.*

FDA Label Image

Figure F (Advair Diskus Spl Graphic 13)

An instructional illustration showing hands holding an ADVAIR DISKUS inhaler with an arrow indicating the direction to slide the lever, demonstrating how to prepare the inhaler for use.*

FDA Label Image

Figure G (Advair Diskus Spl Graphic 14)

An illustration showing a woman actively rinsing her mouth with water over a sink, possibly demonstrating proper oral hygiene or post-inhalation rinsing. A glass of water is placed nearby on the counter next to the sink faucet.*

FDA Label Image

Figure H (Advair Diskus Spl Graphic 15)

ADVAIR DISKUS 100/50 inhalation powder dispenser in purple, containing 60 blisters. The product contains fluticasone propionate and salmeterol with strengths of 100 mcg and 50 mcg per dose. The label includes usage information and the labeler is GlaxoSmithKline LLC.*

FDA Label Image

Advair Diskus 100mcg-50mcg Carton (Advair Diskus Spl Graphic 16)

ADVAIR DISKUS 100 mcg/50 mcg inhalation powder packaging label, containing fluticasone propionate and salmeterol. The label shows the inhalation device containing 1 foil strip of 60 blisters. Manufactured by GlaxoSmithKline LLC, this product is indicated for oral inhalation only.*

FDA Label Image

Advair Diskus 250mcg-50mcg Carton (Advair Diskus Spl Graphic 17)

ADVAIR DISKUS 250 mcg/50 mcg inhalation powder label showing fluticasone propionate and salmeterol. The label includes dosage strength, medication details, and a visual of the purple DISKUS inhalation device. It states the package contains one foil strip of 60 blisters. Manufactured by GlaxoSmithKline LLC.*

FDA Label Image

Advair Diskus 500mcg-50mcg Carton (Advair Diskus Spl Graphic 18)

ADVAIR DISKUS inhalation powder with fluticasone propionate 500 mcg and salmeterol 50 mcg strength shown on the packaging label. The label includes dosage form as powder for oral inhalation, with a purple inhalation device image. It states 1 DISKUS device containing 1 foil strip of 60 blisters. Labeler GlaxoSmithKline LLC and NDC 0173-0697-00 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.